Veru Announces Sabizabulin Data Shows It Can Overcome Drug Resistance To Daraxonrasib With Potent Anticancer Efficacy

Benzinga · 1d ago

Veru Inc. (NASDAQ: VERU) today announces new preclinical data showing that sabizabulin can overcome drug resistance to daraxonrasib (RASONQUE™1 Revolution Medicines) with potent anticancer efficacy (IC50=18.2nM) in daraxonrasib resistant human pancreatic cancer cell line which is a drug concentration that can be achieved with current sabizabulin human dosing with good safety. Based on the new, positive preclinical data, and the previous preclinical and clinical sabizabulin studies, the Company will advance sabizabulin into a planned Phase 2 clinical trial for metastatic KRAS-driven pancreatic cancer progression that has become resistant to the recent FDA approved daraxonrasib.